Santhera Regains U.S., Canadian Rights to Fipamezole from Biovail in 2011

Santhera Pharmaceuticals Holding will regain U.S. and Canadian rights to the fipamezole medicine from Biovail Laboratories as of January 2011, the company said in a statement today.

To contact the editor responsible for this story: Carey Sargent at

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.